Browsing Category
Pharma Industry News
4718 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
BioVie stock tumbles 9% despite promising Parkinson’s drug results as Phase 3 financing concerns loom
BioVie stock falls despite promising bezisterim Parkinson's data. Explore the Phase 3 opportunity, financing risks and investor outlook
RAPP stock gains on RAP-219 clinical success as Wall Street weighs modest treatment benefit
Rapport Therapeutics' RAP-219 trial lifts RAPP stock as investors weigh its bipolar mania potential. Discover the Phase 3 outlook and market risks.
Pharming Group tightens 2026 revenue guidance to $380m–$390m after strong third-quarter sales
Pharming Group Q3 revenue rises 21% to $117.6 million as Joenja sales jump 58%. Explore revised guidance, expenses and investor outlook.
CytoDyn changed CEOs today. What does Robert Hoffman need to deliver next?
CytoDyn has moved former finance chief Robert Hoffman into the CEO role while Jacob Lalezari returns to scientific work, separating corporate execution from research as leronlimab advances deeper into oncology.
Roche signs potential $15bn-plus Hansoh cancer drug deal as ADC race accelerates
Roche Holding AG has expanded its partnership with Hansoh Pharmaceutical Group through a multibillion-dollar antibody-drug conjugate licensing agreement. The deal includes $400 million upfront, $110 million after the first year and potentially more than $15 billion in development, regulatory and commercial milestone payments.
Merck KGaA’s $1.3bn Silence Therapeutics deal makes rare blood cancer a new growth priority
Merck KGaA has agreed to acquire Silence Therapeutics for approximately $1.3 billion in equity value, securing a clinical-stage gene-silencing platform and a promising treatment candidate for polycythemia vera as it expands its rare disease portfolio.
EyePoint is cutting 53% of its workforce. Can DURAVYU’s DME trials rescue the strategy?
EyePoint is ending its pivotal wet AMD programme early and cutting roughly half its workforce after DURAVYU failed a second Phase 3 primary endpoint, leaving two diabetic macular edema trials as the company’s central value driver.
Immunic (NASDAQ: IMUX) adds people chief as ENSURE Phase 3 data approach
Immunic has appointed Jaa Roberson as its first Chief People Officer as the biotech prepares for pivotal multiple sclerosis data that could move it from clinical development toward regulatory and commercial execution.
Cryosite (ASX: CTE) revenue rises 17% as TGA review advances second Sydney clinical trial facility
Cryosite has delivered record first-quarter revenue, stronger operating margins and higher cash flow while advancing a proposed expansion of its Therapeutic Goods Administration licence to cover a second clinical trial and biological storage facility.
What does GSK’s Belgium job plan reveal about its £1.9bn cost reset?
GSK is preparing a major workforce reduction across three Belgian locations as Chief Executive Officer Luke Miels redirects spending toward late-stage medicines, vaccines and a leaner cost structure.